A multicentre, randomised, double-blind, placebo-controlled, cross-over study to evaluate the efficacy, safety and tolerability of MEM 1414 (600 mg) on the allergen-induced late asthmatic response in steroid-free subjects with mild allergic asthma.

Trial Profile

A multicentre, randomised, double-blind, placebo-controlled, cross-over study to evaluate the efficacy, safety and tolerability of MEM 1414 (600 mg) on the allergen-induced late asthmatic response in steroid-free subjects with mild allergic asthma.

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Jun 2015

At a glance

  • Drugs MEM 1414 (Primary)
  • Indications Allergic asthma
  • Focus Therapeutic Use
  • Sponsors Memory Pharmaceuticals
  • Most Recent Events

    • 19 May 2010 Results were presented at the 106th International Conference of the American Thoracic Society.
    • 15 Sep 2009 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials.
    • 22 Dec 2008 Status changed from unconfirmed to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top